Arvinas logo

ArvinasNASDAQ: ARVN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 September 2018

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.58 B
-63%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-51%vs. 3y high
67%vs. sector
-94%vs. 3y high
78%vs. sector

Price

regular market | 3 min ago
$23.05-$0.78(-3.25%)

Dividend

No data over the past 3 years
$102.40 M$60.08 M
$102.40 M-$49.20 M

Analysts recommendations

Institutional Ownership

ARVN Latest News

Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
accesswire.com21 November 2024 Sentiment: -

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.

Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas, Inc.") (NASDAQ:ARVN) concerning possible violations of federal securities laws. On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
accesswire.com19 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
globenewswire.com07 November 2024 Sentiment: POSITIVE

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS ® ) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd.

Arvinas to Participate in Upcoming Investor Conferences
globenewswire.com04 November 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com30 October 2024 Sentiment: POSITIVE

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m.

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
globenewswire.com22 October 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that employees from 16 states participated in the Company's third annual “Arvinas Impact Day,” a company-wide day of service where employees joined forces to give back to their communities, engaging in various volunteer activities that made a tangible difference across the Greater New Haven area and beyond.

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
globenewswire.com21 October 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.

Arvinas to Participate in Upcoming Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

  • 1(current)
  • 2
  • 3

What type of business is Arvinas?

Arvinas, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases by discovering, developing, and commercializing treatment methods that target disease-causing proteins. Arvinas utilizes its patented PROTAC Discovery Engine platform. The company was founded in 2015 and is based in New Haven, Connecticut. The therapeutic focus of the issuer includes oncological diseases, neurological disorders, and other serious illnesses. Arvinas, Inc. has two leading product candidates: ARV-110 - for the treatment of men with metastatic castration-resistant prostate cancer ARV-471 - for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

What sector is Arvinas in?

Arvinas is in the Healthcare sector

What industry is Arvinas in?

Arvinas is in the Biotechnology industry

What country is Arvinas from?

Arvinas is headquartered in United States

When did Arvinas go public?

Arvinas initial public offering (IPO) was on 27 September 2018

What is Arvinas website?

https://www.arvinas.com

Is Arvinas in the S&P 500?

No, Arvinas is not included in the S&P 500 index

Is Arvinas in the NASDAQ 100?

No, Arvinas is not included in the NASDAQ 100 index

Is Arvinas in the Dow Jones?

No, Arvinas is not included in the Dow Jones index

When was Arvinas the previous earnings report?

No data

When does Arvinas earnings report?

The next expected earnings date for Arvinas is 27 February 2025